In Brief: Mallinckrodt/MBI
This article was originally published in The Gray Sheet
Mallinckrodt/MBI: File EU marketing application for FS069, the firms' cardiovascular ultrasound contrast agent designed to enhance visualization of endocardial borders and left ventricular opacification, and to improve doppler signal enhancement. A premarket approval application for FS069 is under review at FDA. The agency's Radiological Devices Panel voted 6-1 to recommend that FDA approve the agent without conditions at its meeting earlier this month ("The Gray Sheet" March 3, p. 9)...
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.